RALEIGH, N.C., Aug. 4, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that the Company is collaborating with America Stem Cell ("ASC") to expand on observations from recent preclinical studies showing that dipeptidylpeptidase (DPPIV) inhibitors improve the efficiency of hematopoietic stem cell (HSC) transplants. HSC transplants are used as a therapeutic approach for many malignant and non-malignant hematological disorders.
